Cancer anorexia and cachexia

Nutrition

Volumn 17, Issue 5, 2001, Pages 438-442

  Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Anorexia; Cachexia; Eicosapentaenoic acid; Lipid mobilizing factor; Proteolysis inducing factor

Indexed keywords

ADENYLATE CYCLASE; APPETITE STIMULANT; CYCLIC AMP; CYPROHEPTADINE; CYTOKINE; GLYCOPROTEIN; ICOSAPENTAENOIC ACID; LIPID MOBILIZER HORMONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; POLYUNSATURATED FATTY ACID; PROSAPOSIN; PROTEASOME; TRYPTOPHAN; UBIQUITIN; UNCLASSIFIED DRUG;

ANOREXIA; CACHEXIA; CANCER; COMPARATIVE STUDY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DRUG EFFICACY; ENERGY EXPENDITURE; ENZYME DEFECT; FOOD INTAKE; HUMAN; LEAN BODY WEIGHT; LIPOLYSIS; MUSCLE ATROPHY; ODOR; PRIORITY JOURNAL; PROTEIN DEGRADATION; SATIETY; SKELETAL MUSCLE; TASTE; TRYPTOPHAN BRAIN LEVEL; URINARY EXCRETION;

ANOREXIA; APPETITE STIMULANTS; BLOOD PROTEINS; CACHEXIA; EICOSANOIC ACIDS; HUMANS; LIPID METABOLISM; MUSCLE, SKELETAL; NEOPLASMS; PEPTIDES; PROTEINS;

EID: 0035000097     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(01)00506-8     Document Type: Conference Paper

References (80)

1. Grosvenor M, Balcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Cancer 1989;63:330
2. Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in cancer bearing and anorexia patients. JPEN 1987;11:219
3. Fearon KCH. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 1992;51:251
4. Costa G, Lane WW, Vincint RG, et al. Weight loss and cachexia in lung cancer. Nutr Cancer 1980;2:98
5. Evans WK, Makuch R, Clamon GH, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 1985;45:3347
6. Kotler DP, Tiemey AR, Culpepper-Morgan JA, Wang J, Pierson RN. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN 1990; 14:454
7. Strent SJ, Beddol AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma 1987;27: 262
8. Costa G. Cachexia, the metabolic component of neoplastic diseases. Prog Exp Tumor Res 1963;3:321
9. Bibby MC, Double JA, Ali SA, et al. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 1987;78:539
10. De Wys WD, Walters K. Abnormalities of taste sensation in cancer patients. Cancer 1975;36:1888
11. Knox LS. Nutrition and cancer. Nurs Clin North Am 1983; 18:97
12. Vigano A, Watanabe S, Bruera E. Anorexia and cachexia in advanced cancer patients. Cancer Surv 1994;21:99
13. Chance WT, Balasubramaniam A, Borchero M, Fischer JE. Refractory hypothalamic adenylate cyclase in anorectic tumour bearing rats. Implications for NPY-induced feeding. Brain Res 1995;691:180
14. Chance WT, Balasubramaniam A, Thompson H, et al. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996;17:797
15. Chance WT, Balasubramaniam A, Dayal R, Brown J, Fischer JE. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994;54:1869
16. Cangiano C, Laviano A, Meguid MM, et al. Effects of administration of oral branched-chain amino acids on anorexia and calorie intake in cancer patients. J Natl Cancer Inst 1996;88:50
17. Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest 1990;86:2014
18. Plata Salaman CR, Oomura Y, Kai Y. Tumor necrosis factor and interleukin-1 beta: suppression of food intake by direct action in the central nervous system. Brain Res 1998;448:106
19. Laviano A, Meguid MM, Yang Z-J, et al. Cracking the riddle of cancer anorexia. Nutrition 1996;12:706
20. Hellerstein MK, Meydani S, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat: Influence of prostaglandins. J Clin Invest 1989;84: 228
21. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999;59:4493
22. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657
23. Downer S, Joel S, Allbright A, et al. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 1993;67: 1102
24. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82: 1127
25. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res 1997;17:657
26. Goldberg RM, Loprinzi CL, Malliard JA. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double blind, placebo-controlled trial. J Clin Oncol 1995;13:2856
27. Shaw JH, Wolfe RR. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. Ann Surg 1987;205:368
28. Drott C, Persson H, Lundholm K. Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin Physiol 1989;9:427
29. Edmonson JH. Fatty acid mobilization and glucose metabolism in patients with cancer. Cancer 1966;19:277
30. Costa G, Bewley P, Aragon M, Siebold J. Anorexia and weight loss in cancer patients. Cancer Treat Rep 1981;65(suppl 5):3
31. Groundwater P, Beck SA, Barton C, et al. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer 1990;62:816
32. Beck SA, Tisdale MJ. Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 1987;47:5919
33. Khan S, Tisdale MJ. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int J Cancer 1999;80:444
34. Berg M, Fraker DL, Alexander HR. Characterization of differentiation factor/ leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-LI adipocytes. Cytokine 1994;6:425
35. Thompson MP, Cooper ST, Parry BR, Tuckey JA. Increased expression of the mRNA for the hormone-sensitive lipase in adipose tissue of cancer patients. Biochim Biophys Acta 1993;1180:236
36. Todorov PT, McDevitt TM, Meyer DJ, et al. Purification and characterization of a tumour lipid-mobilizing factor. Cancer Res 1998;58:2353
37. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998;58:2359
38. Bing C, Brown M, King P, et al. Increased gene expression of brown fat UCP1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res 2000;60:2405
39. Fredrix EW, Soeters PB, Wouters EF, et al. Effect of different tumor types on resting energy expenditure. Cancer Res 1991;51:6138
40. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325
41. Shellock FG, Riedinger MS, Fishbein MC. Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia. J Cancer Res Clin Oncol 1986;111:82
42. Gambardella A, Tortoriello R, Pesce L, et al. Intralipid infusion combined with propranolol administration has favourable metabolic effects in elderly malnourished cancer patients. Metabolism 1994;48:291
43. Lovell BB, Flier JS. Brown adipose tissue, beta 3-adrenergic receptors and obesity. Ann Rev Med Chem 1997;48:307
44. Hyltander A, Daneryd P, Sandström R, Körner U, Lundholm K. β-Adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer 2000;36:330
45. Jeevanandam M, Lowry SF, Horowitz GD, Brennan MF. Cancer cachexia and protein metabolism. Lancet 1984;1:1423
46. Emery PW, Edwards RHT, Rennie MJ, Souhami RL, Halliday D. Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br Med J 1984;289:584
47. Rennie MJ, Edwards RHT, Emery PW, et al. Depressed protein synthesis is the dominant characteristic of muscle wasting and cachexia. Clin Physiol 1983;3:387
48. Lundholm K, Bennegard K, Eden E, et al. Efflux of 3-methylhistidine from the leg of cancer patients who experience weight loss. Cancer Res 1982;42:4807
49. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999; 129:2278
50. Goll DE, Thompson VF, Taylor RG, Christiansen JA. Role of the calpain system in muscle growth. Biochimie 1992;74:225
51. Baracos VE, De Vivo C, Hoyle DHR, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995;268:E996
52. Temparis S, Asensi M, Taillandier D, et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscle of tumor-bearing rats. Cancer Res 1994;54:5568
53. Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998;78:850
54. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumour necrosis factor-o- induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem 1993;125:11
55. Llovera M, Garcia-Marti nez C, Agell N, Lopez-Soriano FJ, Argiles JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscle. Biochem Biophys Res Commun 1997;230:238
56. Li Y-P, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-K5 B activation in response to tumor necrosis factor a. FASEB J 1998;12:871
57. Ebisui C, Tsujinaka T, Morimoto T, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci 1995;89:431
58. Llovera M, Carbo N, Lopez-Soriano J, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 1998;133:83
59. Espat NJ, Auffenberg T, Rosenberg JJ, et al. Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol 1996;271:R185
60. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996;73:1560
61. Maltoni M, Fabbri L, Nanni O, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997;5:130
62. Belizario JE, Katz M, Chenker E, Raw I. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. Br J Cancer 1991;63:705
63. Smith KL, Tisdale MJ. Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer 1993;68:314
64. Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. Nature (Lond) 1996;379:739
65. Todorov PT, McDevitt TM, Cariuk P, et al. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996;56:1256
66. Todorov PT, Deacon M, Tisdale MJ. Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997;272:12279
67. Cariuk P, Lorite MJ, Todorov PT, et al. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997; 76:606
68. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997;76:1035
69. Wigmore SJ, Todorov PT, Barber MD, et al. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000; 87:53
70. Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer 1999;80:1734
71. 12 myoblasts: modulation by eicosapentaenoic acid. Cancer Res 1999;59:5507
72. Hussey HJ, Tisdale MJ. Effect of a cachectic factor on carbohydrate metabolism and attenuation by eicosapentaenoic acid. Br J Cancer 1999;80:1231
73. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991;41:103
74. Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor. Cancer Res 1998;58:4827
75. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991;51:6089
76. Wigmore SJ, Ross JA, Falconer JS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12(suppl):S27
77. Barber MD, Wigmore SJ, Ross JA, Fearon KCH. Eicosapentaenoic acid attenuates cachexia associated with advanced pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 1997;57:204
78. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80
79. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalised malignancy. A randomised controlled trial. Cancer 1998;82:395
80. De Wys WD. Management of cancer cachexia. Semin Oncol 1985;12:452